CEO acquires call options from Stena Sessan

Meda’s CEO, CFO and two other group executives have acquired a total of 600,000 call options from Stena Sessan; these options have a two-year duration, and they entitle the holder to buy 600,000 Meda shares at SEK 80 per share (exercise price). Dilution will not occur for other Meda shareholders because these call options were issued on Stena Sessan’s shareholding.
Stena Sessan is Meda’s largest shareholder. The Black & Scholes valuation model was used to determine the price of these call options.

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.

Documents & Links